JPH06508523A - Iron chelate medium additive - Google Patents
Iron chelate medium additiveInfo
- Publication number
- JPH06508523A JPH06508523A JP5501299A JP50129993A JPH06508523A JP H06508523 A JPH06508523 A JP H06508523A JP 5501299 A JP5501299 A JP 5501299A JP 50129993 A JP50129993 A JP 50129993A JP H06508523 A JPH06508523 A JP H06508523A
- Authority
- JP
- Japan
- Prior art keywords
- citrate
- medium
- iron
- additive
- alkaline earth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/005—Protein-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
Abstract
(57)【要約】本公報は電子出願前の出願データであるため要約のデータは記録されません。 (57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】 鉄キレート培地添加剤 発明の分野 本発明は、哺乳動物細胞の増殖のための培地、主に血清を含まない、又は蛋白質 を含まない培地のための鉄則、並びに咳鉄則を含有する培地に関する。[Detailed description of the invention] Iron chelate medium additive field of invention The present invention provides media for the growth of mammalian cells, primarily serum-free or protein-free. Regarding the golden rule for a culture medium that does not contain , as well as the culture medium that contains a cough golden rule.
発明の背景 極く最近まで、哺乳動物細胞を増殖するための通常の培地は、細胞の増殖および 天然の繁殖のための必要な集団における成長因子の重要な起源として血清を含有 していた。しかし、培地中での血清又は特異的な添加された蛋白質の存在は、次 の不利益を被っている:すなわち、哺乳動物の培養からの所望の蛋白質製品の精 製はより困難でありそして伝染性試剤によって汚染の危険性が増加する。従って 、哺乳動物細胞の培養分野において培地を開発することが重要な目的でありこの 培地中細胞培養に必要な血清中の成分は同1.;月的にかなう非蛋白質の物質で 置き代えられる。従って、血・清を有しないか、又は蛋白質を有しない培地は、 生物学的材料(例えば、モノクローナル抗体、天然又は組換え体医薬等)の製造 において哺乳動物細胞の培養に著るしく重要になってきている。大抵の血清を有 しない培地は、インシュリン、トランスフェリン、セレン、成長因子および成る 種の蛋白質および脂肪源を加えた商業的に入手可能な基礎培地である〔ハミルト ン等、 In Vitro 13 :537−547.1977 ;ハム等、M ethods Enzytsol、 58: 44−93.1979 ; ?シ アタ等、Ce1l Biol。Background of the invention Until very recently, the usual media for growing mammalian cells were Contains serum as an important source of growth factors in populations necessary for natural reproduction Was. However, the presence of serum or specific added proteins in the medium suffer the disadvantages of manufacture is more difficult and increases the risk of contamination by infectious agents. Therefore In the field of mammalian cell culture, developing media is an important objective. The components of serum necessary for cell culture in medium are the same as 1. ;A non-protein substance that meets the needs of the moon. Can be replaced. Therefore, a medium without serum/serum or without protein, Production of biological materials (e.g. monoclonal antibodies, natural or recombinant drugs, etc.) has become of significant importance in the culture of mammalian cells. Has most serum No medium consists of insulin, transferrin, selenium, growth factors and A commercially available basal medium supplemented with seed protein and fat sources [Hamilt Ham et al., M. et al., In Vitro 13:537-547.1977; methods Enzytsol, 58: 44-93.1979;? S Atta et al., Ce1l Biol.
Int、 Rep、 4 ; 43−50.1980 ; Barnes、 B ioTechnology 5 : 534−540 、 1987 ;フォレ ンチニ等、 Am、 Biotech、 Lab、 8 :35−37゜199 0 ;プジャーレ、 J、 Biotech、 15 : 147−154.1 990 ;ヘプレノトCytotechnology 5: 3−14. 19 91)発明の要約 今や血清を有しない培地中鉄起源としてトランスフェリンをシトレートおよび鉄 塩の非蛋白質シトレートにより置換できることが見出された。Int, Rep, 4; 43-50.1980; Barnes, B ioTechnology 5: 534-540, 1987; Foret Nchini et al., Am, Biotech, Lab, 8:35-37°199 0; Pujare, J., Biotech, 15: 147-154.1 990; Heprenoto Cytotechnology 5: 3-14. 19 91) Summary of the invention Citrate and iron transferrin as iron source now in serum-free medium It has been found that the salt can be replaced by non-protein citrate.
従って、本発明は可溶性鉄塩およびアルカリ金属もしくはアルカリ土類金属シト レートの鉄キレートを含んでなる培地添加剤に関する。血清を存しない培地に対 する鉄キレートは従来、例えば鉄−EDTA/クエン酸キレートおよびオーリン 三カルボン酸を含有する培地添加剤を記載するヨーロッパ特許274445に提 案されている0本発明の鉄キレート添加剤は、次の点でヨーロッパ特許274. 445で提案されたものよりも利点を有している:すなわち本発明の鉄キレート 添加剤は、安価な成分から構成され、そして該添加剤は汚染の源となるようなよ り少ない成分を含有する。Therefore, the present invention provides soluble iron salts and alkali metal or alkaline earth metal salts. The present invention relates to a medium additive comprising an iron chelate. For serum-free medium Traditionally, iron chelates used for this purpose are e.g. Filed in European Patent 274445 describing a media additive containing tricarboxylic acids. The proposed iron chelating additive of the present invention is disclosed in European Patent No. 274. 445: the iron chelates of the present invention Additives are made up of inexpensive ingredients, and they are often used as a source of contamination. Contains fewer ingredients.
別の面において、本発明は哺乳動物細胞の増殖のための培地に関し、該培地は可 溶性鉄およびアルカリ金属もしくはアルカリ土類金属シトレートの鉄キレートを 含んでなる。In another aspect, the invention relates to a medium for the growth of mammalian cells, the medium comprising: Iron chelates of soluble iron and alkali metal or alkaline earth metal citrates Contains.
発明の詳細な開示 鉄の沈殿並びに培養される細胞に対する鉄の潜在力のある毒性効果を避けるため 、シトレートキレータ−は培地に添加する前に平衡を発生させるために鉄塩と混 合されるべきである。この平面は、例えば濃厚原液中で、形成され、そしてプロ セスは撹伴、オートクレーブ処理等により加速される。鉄添加側の調製において 、必要な平衡は、アルカリ金属又はアルカリ土類金属シトレートが鉄塩に対して モル過剰で存在する場合、特に鉄塩に対するシトレートの割合が1:1超で50 =1未満である場合、最も好都合に達せられる。Detailed disclosure of the invention To avoid iron precipitation as well as the potential toxic effects of iron on the cells being cultured. , the citrate chelator is mixed with iron salts to generate equilibrium before adding to the medium. should be combined. This plane is formed, for example in a concentrated stock solution, and the Processing is accelerated by stirring, autoclave treatment, etc. In the preparation of the iron addition side , the required equilibrium is that the alkali metal or alkaline earth metal citrate is relative to the iron salt. When present in molar excess, especially when the ratio of citrate to iron salt is more than 1:1, = less than 1, this is most conveniently achieved.
本発明の添加剤中に含まれるための適当な鉄塩は、FeC1z、 FeCI=。Suitable iron salts for inclusion in the additives of the present invention are FeClz, FeCI=.
Fe5(PO4)z 、 Fe(NO3)iおよびFeIzから成る群から選ば れることができる。本発明の添加剤中に含まれるための適当なアルカリ金属もし くはアルカリ土類金属シトレートの例は、Na−シトレート、K−シトレート又 はMg−シトレートである。特に、好ましいB様において、添加剤中に含まれる 鉄塩はFeC1,又はFeC15であり、そしてシトレートはNa−シトレート である。この場合、FeCIz /FeC1zに対するNa−シトレートの好ま しい割合は、2:1〜500 : 1である。Selected from the group consisting of Fe5(PO4)z, Fe(NO3)i and FeIz can be Suitable alkali metals may be used for inclusion in the additives of the invention. Examples of alkaline earth metal citrates include Na-citrate, K-citrate or is Mg-citrate. Particularly, in preferable type B, the additive contains The iron salt is FeC1 or FeC15, and the citrate is Na-citrate. It is. In this case, the preference of Na-citrate over FeCIz/FeClz A suitable ratio is 2:1 to 500:1.
添加剤が含まれることが意図されている培地は、好ましくは哺乳動物細胞を増殖 するための培地であり、本発明の添加剤は哺乳動物細胞が驚くべきことに利用可 能であった安価な鉄起源を構成する。The medium intended to contain additives preferably grows mammalian cells. The additives of the present invention are surprisingly available to mammalian cells. It was an inexpensive source of iron.
従って、培地は例えば低血清培地又は、好ましくは血清を有しないか又は蛍白質 を有しない培地であり、この培地において非蛋白質鉄剤を提供することが重要で ある。従来、真水のシトレートテトラハイメナサーモフィ−Tetrah me nd thermo hila)は唯一の鉄源として前キレート化鉄シトレート を利用することができることが記載されているけれども(注、P、 B、スーザ ーヤノセン アンドL、ラスムセン、ハL匹虱り旦L 且ム 1982.457 −460頁;L、ラスムセン等、丈−並旦一ハ旦工理ム155−158頁;哺乳 動物細胞は又血清を有しない培地中、鉄源としてシトレート/塩化鉄キレートを 利用することは示唆されていない。生物学的に言えば、栄養成分の豊富な環境下 でかつ相当の浸透圧の下で存在する哺乳動物細胞が栄養荊−プール環境中に生存 する特別な原始的真水生物、と同様の方法で栄養剤を同化し得ることは全く驚く べきことである。Thus, the medium may be, for example, a low serum medium or preferably serum-free or fluorescent. It is important to provide a non-protein iron supplement in this medium. be. Conventionally, fresh water citrate tetrahymena thermophyte nd thermohila) uses prechelated iron citrate as the sole iron source. Although it is stated that it is possible to use (Note, P, B, Sousa - Janosen And L, Rasmussen, HaL 1982.457 - p. 460; L. Rasmussen et al.; Animal cells also receive citrate/iron chloride chelate as an iron source in serum-free medium. It is not suggested that it be used. Biologically speaking, in an environment rich in nutrients Mammalian cells exist in a nutrient pool environment that is large and under considerable osmotic pressure. It is quite surprising that special primitive freshwater organisms could assimilate nutrients in a similar way to It is the right thing to do.
本発明を次の実施例によって更に説明するが、いかなる場合も本発明の範囲を制 限するものではない。The invention is further illustrated by the following examples, which in no way limit the scope of the invention. It is not limited.
例1.−則ぴJLB町 唯−の鉄fi (SFNMT)としてトランスフェリンを有するBHK細胞(マ シアーク等(1980、同表)により記載の如し)に対し血清を有しない普通培 地を含むコーテッド T−フラスコ中で培養される着生のBHKEII胞をトラ ンスフェリン(SFNM−)を欠いているが、Na −シトレートおよび塩化鉄 のキレート化原液を加えた血清な有しない栄養培地を含有する一連のコーテッド ニーフラスコに付随して接種した。実験1〜3は、異なる持続時間を有しそして 実験のシトレート濃度はそれぞれ2 mM、2 mMおよび51(最終濃度)で あった、平行の対象培養株をSFN肘中で培養した。Example 1. - Noripi JLB Town BHK cells (matrix) have transferrin as the only iron fi(SFNMT). (as described by Siark et al. (1980, same table)) in normal medium without serum. Transplant epiphytic BHKE II cells cultured in coated T-flasks containing soil. Lacks sferrin (SFNM-) but contains Na-citrate and iron chloride Coated series containing nutrient media without serum plus chelated stock solution of It was inoculated in a knee flask. Experiments 1-3 had different durations and Citrate concentrations in the experiment were 2 mM, 2 mM and 51 (final concentration), respectively. A parallel control culture was grown in the SFN elbow.
各細胞培養物を、使用した培地の代わりに同し種類の新しい血清を有しない培地 を用い又は同じ種類の新しい血清を有しない培地を有する新しいT−フラスコに サブ培養して独立に処理した。実験の終りに、各培地におけるは培加の総数を計 算した:*シトレートおよび塩化鉄はSFNMTに添加されながった。Each cell culture was grown in fresh serum-free medium of the same type in place of the medium used. or into a new T-flask with fresh serum-free medium of the same type. Subcultures were processed independently. At the end of the experiment, count the total number of cultures in each medium. Calculated: *Citrate and iron chloride were not added to SFNMT.
例2.ff 2IIIMのシトレートおよび100μMのFeCl5 (最終濃度)をもたら すキレート化シトレート鉄原液を加えたBHK細胞(例1参照)のためのSFN M含有のスピンネルフラスコにBHK細胞を接種した6wi胞をコーテッドマイ クロキャリアに付着せしめた数時間の後、細胞は拡散し、増殖しそして実験が終 了したとき2週間以上本質的に融合性でかつ健全であった。Example 2. ff 2IIIM citrate and 100 μM FeCl5 (final concentration) SFN for BHK cells (see Example 1) with chelated iron citrate stock solution 6wi cells inoculated with BHK cells were placed in a spinnel flask containing M-coated microorganisms. After several hours of attachment to the crocarriers, the cells spread, proliferate, and the experiment is terminated. The patient remained essentially confluent and healthy for more than two weeks when completed.
例3.二赳坦皿 唯−の鉄源(SFN?lT)としてトランスフェリンを有するCHO細胞(バー ム等(1979,同上)によって記載の如く)に対し血清を有しない普通培地を 含有するコーテッドニーフラスコ中で培養した付着CHO細胞を、トランスフェ リン(SFNM−)を欠いているがNa−シトレートと塩化鉄のキレート化原液 を加えた血清を有しない普通培地を有する一連のコーテッドニーフラスコ内に随 伴して接種した。実験lおよび2は異なる接待期間を有しそして実験のシトレー トの濃度は2IIIM(最終濃度)であった。平行の対象培養株をSFNMT中 で培養した。Example 3. Two-sided plate CHO cells (Barr) with transferrin as the only iron source (SFN?IT) (1979, supra)) using normal medium without serum. Adherent CHO cells cultured in coated knee flasks containing Chelated stock solution of Na-citrate and iron chloride lacking phosphorus (SFNM-) in a series of coated knee flasks with normal medium without serum supplemented with It was also inoculated. Experiments I and 2 had different reception periods and The concentration of the sample was 2IIIM (final concentration). Parallel target cultures in SFNMT It was cultured in
各細胞培養物を、用いた培地の代わりに同じ種類の新しい血清を有しない培地を 用い又は同じ種類の新しい血清を有しない培地を有する新しいT−フラスコにサ ブ培養して独立に処理した。Replace each cell culture with fresh serum-free medium of the same type in place of the medium used. or into a new T-flask with fresh serum-free medium of the same type. cultured and treated independently.
実験の終りに、各培地における培加の総数を計算した:*シトレートおよび塩化 鉄はSFNMTに添加しなかった。At the end of the experiment, the total number of cultures in each medium was calculated: *Citrate and Chloride No iron was added to the SFNMT.
例4.−ΩWll巳 CHO細胞を、それぞれ21のシトレートおよび100および300μmの(最 終濃度)のFeCl2をもたらすキレート化シトレート−塩化鉄原液を加えたC HO細胞(例3参照)に対しSFNM−を含有する2個のスピン皐ルフラスコに 接種した。細胞をコーテッドマイクロキャリアに付着せしめた数時間後、細胞は 拡散し、増殖しそして実験が終了したとき2週間以上本質的に融合性でかつ健全 であった。Example 4. -ΩWll Snake CHO cells were incubated with 21 citrate and 100 and 300 μm (maximum), respectively. C with addition of chelated citrate-iron chloride stock solution resulting in FeCl2 (final concentration) HO cells (see Example 3) in two spinner flasks containing SFNM- Inoculated. Several hours after cells were attached to the coated microcarriers, the cells Spread, proliferate and remain essentially confluent and healthy for more than 2 weeks when the experiment is finished. Met.
例5.を妃Il 唯一の鉄! (SFNMT )としてトランスフェリンを有するRPMIへ一ス の血清を有しない普通培地(シャクター1989. TIBTECH,7、24 8−253)を含有するT−フラスコ中での懸濁培養において培養したSP 2 10骨髄腫細胞を、トランスフェリン(SFNM−1を欠いているがNa−シト レートおよび塩化鉄のキレート化原液を加えた血清を有しない普通培地を含有す る一連のT−フラスコ内に付随して接種した。Example 5. Princess Il The only iron! One step to RPMI with transferrin as (SFNMT) Normal medium without serum (Schacter 1989. TIBTECH, 7, 24 SP2 cultured in suspension culture in T-flasks containing 8-253) 10 Myeloma cells were incubated with transferrin (lacking SFNM-1 but with Na-cytophosphate). containing serum-free normal medium supplemented with a chelating stock solution of iron chloride and iron chloride. The cells were inoculated concomitantly into a series of T-flasks.
各細胞培養物を、用いた培地の代替に関し同し種類の新たな血清を有しない培地 を用い、又は同し種類の新たな血清を有しない培地を含有する新しいT−フラス コ内にサブ培養することにより独立に処理した。実験の終りに、各培地の培加の 総数を計算した。Each cell culture was grown in fresh serum-free medium of the same type for replacement of the medium used. or a new T-flas containing fresh serum-free medium of the same type. The cells were treated independently by sub-cultivation within a co-culture. At the end of the experiment, the culture of each medium The total number was calculated.
ギシトレートおよび塩化鉄はSFMNTに加えながった。Gycitrate and iron chloride were not added to the SFMNTs.
例6.ハイプリドーマ 唯一の鉄! (SFNMT )としてトランスフェリンを有するハイブリドーマ 細胞(シャクター1989. TIBTECH,7、248−253)C対すル RP?IIベースの血清を有しない普通培地を含有するT−フラスコ中の懸濁培 養中で培養したSP210ベースのハイブリドーマ細胞を、トランスフェリン( SFNM−)を欠いているがNa−シトレートおよび塩化鉄のキレート化原液を 加えた血清を有しない普通培地を含有する一連のT−フラスコに付随的に接種し た。Example 6. hyperidoma The only iron! Hybridoma with transferrin as (SFNMT) cells (Schacter 1989. TIBTECH, 7, 248-253) RP? Suspension medium in T-flasks containing normal medium without II-based serum SP210-based hybridoma cells cultured in culture were treated with transferrin ( SFNM-) but with a chelated stock solution of Na-citrate and iron chloride. Concomitantly inoculate a series of T-flasks containing normal medium without added serum. Ta.
各細胞培養物を、用いた培地の代替に関し同じ種類の新たな血清を有しない培地 を用い、2は同じ種類の新たな血清を有しない培地を含有する新しいT−フラス コ内にサブ培養することにより独立に処理した。実験の終りに、各培地の培加の 総数を計算した。Each cell culture was grown in fresh serum-free medium of the same type with respect to the replacement of the medium used. 2 is a new T-flas containing fresh serum-free medium of the same type. The cells were treated independently by sub-cultivation within a co-culture. At the end of the experiment, the culture of each medium The total number was calculated.
*シトレートおよび塩化鉄はSFN?ITに加えなかった。*Are citrate and iron chloride SFN? I didn't add it to IT.
補正書の翻訳文提出書 (特許法第184条の8) 平成5年12月zo日Submission of translation of written amendment (Article 184-8 of the Patent Act) December 1993
Claims (17)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91610054 | 1991-06-21 | ||
DK91610054.8 | 1991-06-21 | ||
PCT/DK1992/000190 WO1993000423A1 (en) | 1991-06-21 | 1992-06-18 | Iron chelate culture medium additive |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH06508523A true JPH06508523A (en) | 1994-09-29 |
Family
ID=8208780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5501299A Pending JPH06508523A (en) | 1991-06-21 | 1992-06-18 | Iron chelate medium additive |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0593539A1 (en) |
JP (1) | JPH06508523A (en) |
AU (1) | AU2196892A (en) |
CA (1) | CA2111984A1 (en) |
WO (1) | WO1993000423A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010000094A (en) * | 2002-03-05 | 2010-01-07 | F Hoffmann La Roche Ag | Improved method for growing mammalian cells in vitro |
JP2014530620A (en) * | 2011-10-21 | 2014-11-20 | ファイザー・インク | Addition of iron to improve cell culture |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2243827B2 (en) | 1996-08-30 | 2017-11-22 | Life Technologies Corporation | Serum-free mammalian cell culture medium, and uses thereof |
US6767741B1 (en) | 1999-08-27 | 2004-07-27 | Invitrogen Corporation | Metal binding compounds and their use in cell culture medium compositions |
AU7081500A (en) * | 1999-08-27 | 2001-03-26 | Invitrogen Corporation | Metal binding compounds and their use in cell culture medium compositions |
US20030096414A1 (en) * | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
GB2404665B (en) * | 2003-08-08 | 2005-07-06 | Cambridge Antibody Tech | Cell culture |
ATE359359T1 (en) * | 2003-08-08 | 2007-05-15 | Cambridge Antibody Tech | MYELOMA CELL CULTURE IN A TRANSFERRIN-FREE MEDIUM WITH LOW IRON |
CA2585547A1 (en) | 2004-10-29 | 2006-05-11 | Centocor, Inc. | Chemically defined media compositions |
JP5431361B2 (en) | 2008-01-09 | 2014-03-05 | セルカ ゲーエムベーハー | Improved culture medium additive and method of using the same |
EP3778868B1 (en) * | 2019-08-16 | 2022-01-26 | UGA Biopharma GmbH | Cell culture medium for cultivating cells, method for culturing cells and method for expressing at least one recombinant protein in a cell culture |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS262822B1 (en) * | 1986-10-03 | 1989-04-14 | Kovar Jan | Synthetic medium for the cultivation of myelomic cells |
NO162160C (en) * | 1987-01-09 | 1989-11-15 | Medi Cult As | SERUM-FREE GROWTH MEDIUM AND USE THEREOF. |
-
1992
- 1992-06-18 JP JP5501299A patent/JPH06508523A/en active Pending
- 1992-06-18 WO PCT/DK1992/000190 patent/WO1993000423A1/en not_active Application Discontinuation
- 1992-06-18 AU AU21968/92A patent/AU2196892A/en not_active Abandoned
- 1992-06-18 CA CA 2111984 patent/CA2111984A1/en not_active Abandoned
- 1992-06-18 EP EP92913614A patent/EP0593539A1/en not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010000094A (en) * | 2002-03-05 | 2010-01-07 | F Hoffmann La Roche Ag | Improved method for growing mammalian cells in vitro |
JP2014530620A (en) * | 2011-10-21 | 2014-11-20 | ファイザー・インク | Addition of iron to improve cell culture |
Also Published As
Publication number | Publication date |
---|---|
WO1993000423A1 (en) | 1993-01-07 |
CA2111984A1 (en) | 1993-01-07 |
EP0593539A1 (en) | 1994-04-27 |
AU2196892A (en) | 1993-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5045467A (en) | Serum-free growth medium and use thereof | |
Nakabayashi et al. | Growth of human hepatoma cell lines with differentiated functions in chemically defined medium | |
US6475725B1 (en) | Recombinant cell clones having increased stability and methods of making and using the same | |
JPH06511389A (en) | animal cell culture | |
JPH06508523A (en) | Iron chelate medium additive | |
JP6990659B2 (en) | Chemically defined medium for culturing cancer stem cell (CSC) -containing cell populations | |
CN102317440A (en) | Improved culture medium additive and application method thereof | |
AU761988B2 (en) | C3A serum-free clonal cell line and methods of use | |
ES2267280T3 (en) | STABLE RECOMBINANT CELL CLONE, ITS PREPARATION AND USE OF IT. | |
JP4972261B2 (en) | Metal binding compounds and their use in cell culture media compositions | |
US6767741B1 (en) | Metal binding compounds and their use in cell culture medium compositions | |
US5468635A (en) | In vitro method for stimulating cell growth by culturing cells in a serum-free culture medium comprising human lysozyme | |
JP2859679B2 (en) | New cell line | |
CN100432218C (en) | Embryo cattle serum substitute without serum for animal cell culture | |
US4879222A (en) | Method of isolating tumor-secreted products using a novel protein-free medium | |
US5602025A (en) | Non-tumorigenic cell lines for expression of genes | |
JP2850430B2 (en) | Serum-free medium for cell culture | |
US20120264208A1 (en) | Materials and methods for enhanced iron uptake in cell culture | |
CN115449503A (en) | Method for generating human liver parenchymal cells by in-vitro induction of IPS (IPS) cell differentiation | |
JPS6163280A (en) | Method for high-density cultivation of animal cell | |
JPH03201981A (en) | Preparation of serum-free medium for cell culture | |
JPS6163279A (en) | Method for high-density cultivation of lymphoblastoid cell |